Navigation Links
S*BIO's JAK2 Inhibitor SB1518 Granted Orphan Drug Designation by European Commission (EC) for the Treatment of Myelofibrosis (MF)
Date:10/18/2010

SINGAPORE, Oct. 18 /PRNewswire/ -- S*BIO Pte Ltd today announced that the European Commission (EC) has granted orphan drug designation to SB1518, its potent and orally active JAK2 inhibitor for the treatment of primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF).  SB1518 has also received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of the same disorder.

S*BIO recently reported positive safety and tolerability data from an Australian Phase 1 study in 20 patients treated with SB1518. Results were consistent with the data from SB1518's U.S.  Phase 1 trials in which safety, tolerability and activity in different disease states had been observed. S*BIO is currently in Phase 2 MF trials with SB1518, to further test its safety and efficacy.

"The orphan drug designation strengthens our regulatory strategy for SB1518 and potentially expands our marketing exclusivity in the EU after approval," said Dr. Jan-Anders Karlsson, CEO of S*BIO.  "There is a great unmet medical need in Europe and around the world for an effective and safe treatment of MF and we are confident that SB1518 has the potential to address this need."  

Orphan drug designation in the European Union (EU) is granted to drug candidates intended for the diagnosis, prevention and treatment of diseases that affect no more than five in 10,000 people within the EU and no other therapies exists or where new treatments could offer significant benefit over current therapies.  Orphan drug designation for SB1518 will entitle S*BIO to a range of incentives including protocol assistance, reduction in registration fees and eligibility for grants and initiatives supporting research and development related to this orphan designation, both at the European level, and at the level of the member states. For marketing approved products, the orphan drug statu
'/>"/>

SOURCE S*BIO
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. For the Treatment of Rheumatoid Arthritis, Surveyed European Rheumatologists Expect Well-Established TNF-Alpha Inhibitors to Lose Considerable Patient Share to Newer Agents in This Drug Class
2. For Multiple Myeloma Treatment, More Surveyed European Clinicians Consider the Combination of Immunomodulatory Agents and Proteasome Inhibitors Promising With Respect to Efficacy Than Any Other Drug Regimen Combinations
3. N30 Pharma Initiates Phase 1 Trials of Novel Reductase Inhibitor
4. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
5. ViroPharma Files Prior Approval Supplement (PAS) for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
6. FDA: Possible Fracture Risk With High Dose, Long-term Use of Proton Pump Inhibitors
7. Proton Pump Inhibitor DEXILANT(TM) (dexlansoprazole) Now Available in U.S. Pharmacies
8. Portola Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of PRT062607, an Oral, Syk-Specific Inhibitor for Chronic Inflammatory Disease Indications
9. Genomic Health Announces Publication of Study Using Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated With Aromatase Inhibitors
10. Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors with Plavix(R) (clopidogrel bisulfate)
11. Neurocrine Advances VMAT2 Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)...  Excite Medical was established by its President, ... Medical, under the leadership of Mr. Musallam , ... solid track record of providing unparalleled service and support ... Photo - http://photos.prnewswire.com/prnh/20150529/219412 ... possible, in large part, due to Mr. Musallam,s ...
(Date:5/29/2015)... 28, 2015 Research and Markets ( http://www.researchandmarkets.com/research/64lx2w/north_america_mri ... America MRI Market - Growth, Trends And Forecasts (2014 ... The North American MRI systems market is estimated to ... $1.58 billion by 2020 with a CAGR of 2.9% ... types namely, the open system, closed system and the ...
(Date:5/29/2015)... , May 29, 2015 A six-hour certification ... is being presented at the Cannabis World Congress & ... New York, NY .  Taking place on Wednesday, ... dedicated day of education at the leading event on the ... Led by Clover Leaf University, the first cannabis ...
Breaking Medicine Technology:North America MRI Market - Growth, Trends And Forecasts 2014-2019 with GE, Hitachi Medical, Philips Healthcare, Siemens Healthcare & Toshiba Medical Systems Dominating 2Cannabis Business Certification and Career Workshops Presented at New York Trade Show & Conference 2Cannabis Business Certification and Career Workshops Presented at New York Trade Show & Conference 3Cannabis Business Certification and Career Workshops Presented at New York Trade Show & Conference 4
... Tyrima Demonstrates Good Safety Profile and Excellent,Pharmacokinetic Properties ... /PRNewswire/ --,CeNeRx BioPharma, Inc., a clinical stage company ... central,nervous system, today announced top-line results from a ... for the treatment,of depression and anxiety. In this ...
... /PRNewswire-FirstCall/ - Oncolytics,Biotech Inc. announced today ... reovirus in combination with gemcitabine is ... Cancer Research (AACR),website at <a target="_blank" ... at <a target="_blank" href=,"http://www.oncolyticsbiotech.com/">www.oncolyticsbiotech.com .,The abstract ...
Cached Medicine Technology:CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant 2CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant 3Oncolytics Biotech Inc. Collaborators to Present,Reovirus/Gemcitabine Combination Research at AACR Annual Meeting 2Oncolytics Biotech Inc. Collaborators to Present,Reovirus/Gemcitabine Combination Research at AACR Annual Meeting 3
(Date:5/29/2015)... LAKE, CO (PRWEB) May 29, 2015 ... brand new addiction, substance abuse, and co-occurring mental ... celebration and ribbon cutting for the general public ... June 2nd. , The Recovery Village at Palmer ... and intensive outpatient programming, utilizing traditional and evidence-based ...
(Date:5/29/2015)... 29, 2015 On May 21, 2015, Elle ... When You Get Botox ?” reported on the four ... Elle partnered with Google to determine these results and then ... question in California, for example, is how to keep ... search query is what's the appropriate age to start receiving ...
(Date:5/29/2015)... 29, 2015 Johnson & Johnson ... confidential Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ) settlement with ... to his use of the antipsychotic medication. According ... for the third bellwether trial to involve male ... underway in Pennsylvania’s Philadelphia Court of Common Pleas, ...
(Date:5/29/2015)... FL (PRWEB) May 29, 2015 ... Utah, recently partnered with Stratus Video ... which will facilitate better communication and timely ... (LEP) and hearing loss. Stratus’ video remote ... in-house translators, enabling staff to quickly access ...
(Date:5/29/2015)... Mediaplanet has joined forces with Colorescience ... Skin Health is a cross-platform campaign with a national ... New York, Los Angeles, and Chicago, the campaign is ... counterpart will reach a national audience through one of ... Skin Health campaign and Colorescience, click here . ...
Breaking Medicine News(10 mins):Health News:Advanced Recovery Systems Announces the Opening of The Recovery Village at Palmer Lake 2Health News:Botox, Wrinkles and Double Chins: The Most-Asked Beauty Problems According to Google 2Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 2Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 3Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 2Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 3Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 4Health News:Mediaplanet Launches “Skin Health” Campaign Featuring Colorescience 2
... indelible impact on the lives of many in 2004 and ... ,The most recent data enabled by the AMA ... to CVD, at 406 deaths per 100,000 people. Minnesota portrayed ... 100,000 people. ,The statistics also pointed out ...
... A comprehensive review published in the January 1st issue ... diseases// characterized by selective cell loss, narcolepsy may be ... in genetically susceptible individuals - a possible contradiction to ... responses and stressful life events are factors that may ...
... 60-year-old woman has brought about a revolution in the lives ... determined retiree from Hong Kong, decided one day to live ... there. That momentous decision has made a huge difference to ... is the only nurse at the Tanshan Leper Rehabilitation Village ...
... Chandigarh: Children, pregnant and lactating women and adolescent ... from the state government for their nutritional needs. ... Monday announced enhanced quantum for supplementary nutritional needs ... Development Service (ICDS) scheme. ,She said ...
... down on calories could help in preventing or delaying ... University of Alabama at Birmingham suggest that a key ... body composition (being lean or obese) and whether calories ... the risk of cancer., ,During a study conducted ...
... your New Year resolutions, The Alliance for Aging Research// has ... both physical as well as mental exercise to stay fighting ... Alliance for Aging Research said, "There is a lot we ... or lessen the cognitive decline that often comes with aging. ...
Cached Medicine News:Health News:Narcolepsy May Be Caused By Environmental Exposures: Study 2Health News:A ‘Good Samaritan’ to the Aid of Lepe 2Health News:A ‘Good Samaritan’ to the Aid of Lepe 3
...
... features an advanced design that accommodates both ... gives surgeons the flexibility to easily customize ... is built-in to every aspect of the ... Secure-Twist anti-migration system to the screw options ...
... is designed to meet the clinical challenges ... attached locking mechanism and the choice of ... variable angle screws for ease of implantation ... plate system allows the surgeon the versatility ...
... Revolutions start with small things. ... is one of the trailblazers of ... reflecting the,trend towards ever smaller access ... the operation site. ,The HiLAN XS ...
Medicine Products: